Clik here to view.
GC LabCell and GC Cell to Merge, Creating a Premier Cell Therapy Company
YONGIN, South Korea GC LabCell (KOSDAQ: 144510) and GC Cell (KOSDAQ: 031390) today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. The...
View ArticleClik here to view.
Guided Therapeutics Receives News from Chinese State Food and Drug...
PEACHTREE CORNERS, Ga. Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva™ Advanced Cervical Scan, based on its patented biophotonic technology, announced today its Chinese...
View ArticleClik here to view.
Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in...
CAMBRIDGE, Mass. Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and its partner in Greater China,...
View ArticleClik here to view.
Olympus to Support Endoscopic AI Diagnosis Education for Doctors in Thailand
TOKYO Olympus Corporation (Representative Executive Officer, President and CEO: Yasuo Takeuchi) took part in a ground-breaking project as a business promoter, in cooperation with the Ministry of...
View ArticleClik here to view.
Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture
OXFORD & SHANGHAI Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron）, a Shanghai based company focused on...
View ArticleClik here to view.
冠科生物投资于商业领导力
圣迭戈 (美国商业资讯)–JSR生命科学公司旗下冠科生物今天宣布，任命Alex Slater为北美暨欧洲业务开发副总裁。在此职位上，Slater先生将负责公司现有服务阵容的持续增长，并为拓展新服务奠定基础。...
View ArticleClik here to view.
Omniscient Neurotechnology Launches Quicktome™ Brain Mapping Platform for...
SYDNEY, Australia Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping software company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for...
View ArticleClik here to view.
クラウン・バイオサイエンスが商業幹部職の新設に投資
サンディエゴ （ビジネスワイヤ） — JSRライフサイエンス傘下のクラウン・バイオサイエンスは本日、アレックス・スレーターを事業開発担当バイスプレジデント（北米・欧州）に任命したことを発表します。スレーターはこの役職で、当社の既存サービスポートフォリオを継続的に成長させ、新サービスを拡大するための基盤を築く業務を担当します。...
View ArticleClik here to view.
Synaffix宣布与普方生物达成价值2.46亿美元的ADC合作
荷兰阿姆斯特丹 (美国商业资讯)– Synaffix B.V.,一家专注于将其临床阶段抗体偶联药物（ADC）技术平台商业化的生物技术公司，今天宣布与普方生物，一家抗肿瘤生物药研发公司，签署了一份非排他性的许可协议，该技术可以使ADC药物具有同类最佳的治疗指数。 基于此次合作，Synaffix将提供多个新型的有效载荷连接子技术，包括GlycoConnect™糖苷偶联技术和极性的...
View ArticleClik here to view.
Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic...
SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...
View ArticleClik here to view.
Twist Bioscience社がMOLCURE社の人工知能技術を導入し、抗体医薬品の探索を強化
米国カリフォルニア州サウス ビジネスワイヤ） — サンフランシスコと日本川崎 – 半導体プラットフォームを用いた高品質な合成DNAを提供し、顧客の成功を支援しているTwist Bioscience社（Nasdaq:...
View ArticleClik here to view.
Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
HOUSTON ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas...
View ArticleClik here to view.
Deargen Signs Agreement With Sookmyung Women’s University Research & Business...
SEOUL, South Korea Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced on July 27 that it signed an agreement with Sookmyung...
View ArticleClik here to view.
ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh,...
SINGAPORE & SAN DIEGO ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson,...
View ArticleClik here to view.
FDA Clears Promega OncoMate™ MSI Dx Analysis System
MADISON, Wis. Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer. The OncoMate™...
View ArticleClik here to view.
株式会社KORTUCはピボタル第II相試験（革新的ながん治療放射線増感剤）の加速にむけ、アクサ生命より資金調達を実施
ロンドン & ニューヨーク & 東京 （ビジネスワイヤ） — がんの放射線治療効果を高める放射線増感剤KORTUCの臨床開発及び製品開発を行なうスタートアップ企業、株式会社KORTUC（以下 KORTUC）はアクサ生命保険株式会社（以下 アクサ生命）からの資金調達を実施しました。 KORTUCは本資金調達により、英国で実施中の承認申請取得の為の試験（以下...
View ArticleClik here to view.
KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II...
LONDON & NEW YORK & TOKYO Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the...
View ArticleClik here to view.
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on...
View ArticleClik here to view.
Clik here to view.
Shire社がAbbVie社から受領した違約金に係る税務評価に関する アイルランド税務不服審査委員会による裁定について
大阪 当社は、2021年7月30日（アイルランド現地時間）、Shire plc（以下「Shire社」）が2014年10月にAbbVie...
View Article